Talal Derani
Neuro-ophthalmology · Detroit, MINPI 1841635570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $209,461 of the $274,109 with a category attached, or 76.4%. 33 manufacturers reported payments, led by AstraZeneca at 31.8% of the total. Reporting peaked in 2023 at $107,435 and has fallen 100.0% since, to $19 in 2025.
Across 526 payments — averaging $521.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$87K
- EMD Serono, Inc.$67K
- Biogen$42K
- Amgen$36K
- Sanofi$22K
- Genentech USA, Inc.$14K
- plus $6K from 27 others
Across 14 payments — averaging $1370.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$19K
What the payments were for
- Consulting fees$36,43013%
- Speaking & faculty fees$209,46176%
- Travel & lodging$15,9366%
- Food & beverage$12,0774%
- Education$1860%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 97 | $87,288 |
| EMD Serono, Inc. | 94 | $66,802 |
| Biogen | 61 | $42,161 |
| Amgen(2 entities) | 42 | $36,237 |
| Sanofi | 35 | $21,559 |
| Genentech USA, Inc. | 51 | $13,746 |
| TG Therapeutics, Inc. | 9 | $2,603 |
| Genentech, Inc. | 3 | $1,331 |
| Novartis | 41 | $739 |
| Bristol Myers Squibb | 25 | $453 |
| AbbVie(2 entities) | 15 | $210 |
| Acorda Therapeutics, Inc | 9 | $188 |
| Johnson & Johnson | 6 | $111 |
| Banner Life Sciences, LLC | 4 | $88 |
| Avanir Pharmaceuticals, Inc. | 5 | $85 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 1 | $48 |
| Mylan Specialty L.p. | 2 | $37 |
| Aquestive Therapeutics, Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| SK Life Science, Inc. | 2 | $27 |
| Tanabe Pharma America, Inc. | 2 | $27 |
| Merz North America, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuro-ophthalmology providers in Michiganto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 12 | $793 |
| Gabapentin | 39 | $375 |
| Baclofen | 18 | $349 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in Detroit
- Ayat Alni'matDetroit$283
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.